EDIT
EDIT
NASDAQ · Biotechnology

Editas Medicine Inc

$2.23
-0.09 (-3.88%)
As of Mar 29, 10:36 PM ET ·
Financial Highlights (FY 2026)
Revenue
44.69M
Net Income
-176,521,931
Gross Margin
Profit Margin
-395.0%
Rev Growth
+27.2%
D/E Ratio
2.15
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 64.4% 64.4%
Operating Margin -394.9% -355.4% 24.8% 21.2%
Profit Margin -395.0% -375.3% 14.4% 17.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 44.69M 35.15M 30.54M 27.97M
Gross Profit 19.66M 18.00M
Operating Income -176,469,837 -124,909,833 7.57M 5.94M
Net Income -176,521,931 -124,946,706 4.38M 4.75M
Gross Margin 64.4% 64.4%
Operating Margin -394.9% -355.4% 24.8% 21.2%
Profit Margin -395.0% -375.3% 14.4% 17.0%
Rev Growth +27.2% +27.2% +16.6% +5.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 77.46M 77.46M 59.55M 55.44M
Total Equity 36.07M 36.07M 93.22M 102.72M
D/E Ratio 2.15 2.15 0.64 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -173,057,262 -129,299,566 9.59M 9.00M
Free Cash Flow 5.15M 6.45M